Calidi Biotherapeutics

$CLDI is engineering the future of genetic medicine, delivering therapies precisely to sites of disease to advance oncology and other indications. Learn more about our unique approach to precisely delivering genetic medicines to sites of disease: calidibio.com

📣 We are excited to announce that CEO, Dr. Eric Poma, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025 at the Lotte New York Palace Hotel in NYC. Read more here: globenewswire.com/news-release/2… #calidi #redtail $CLDI

We are thrilled to announce that CLD‑201 (SuperNova), our allogeneic adipose stem-cell loaded oncolytic virus, has received FDA Fast Track designation for the treatment of patients with soft tissue sarcoma. Read more here: calidibio.com/calidi-biother… #CLD201 #calidi #FastTrack

We are excited to announce a shareholder letter from CEO, Eric Poma, PhD, highlighting changes in Calidi's leadership, its focus and priorities, and in its balance sheet and operating expenses. Read more here: calidibio.com/calidi-biother… #calidi #redtail #virotherapy $CLDI

Calidi Biotherapeutics CEO, Eric Poma, represented the company at the BIO conference in Boston last week! Dr. Poma had a series of productive meetings that highlighted Calidi’s innovative approach and deep commitment to advancing immuno-oncology. #calidi #virotherapy #BIO $CLDI

@CalidiBio today announced the presentation of its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology @ASCO Annual Meeting. Read more here: calidibio.com/calidi-biother… #calidi #redtail #systemic #asco $CLDI

📣 Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights Read more to learn about Calidi's recent corporate developments: ir.calidibio.com/news/news-deta… #calidi #redtail #virotherapy $CLDI

@CalidiBio today announced the succession of its CEO, Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi. Mr. Camaisa will continue to serve as a member of the Board. Read more here: calidibio.com/newsroom/post/…

We are thrilled to announce the appointment of Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor. Read more here: calidibio.com/newsroom/post/…

@CalidiBio is pleased to report fourth quarter and full-year 2024 financial results and recent operational highlights. These include: Read more about these exciting updates here: calidibio.com/newsroom/post/…

🧠 Calidi Biotherapeutics $CLDI Advances Virotherapy for Aggressive Brain Cancer @CalidiBio, in partnership with @CityofHope, shared promising progress from its Phase 1 trial of CLD-101, a novel stem cell-based virotherapy for recurrent high-grade glioma—one of the deadliest brain cancers. 💡 Why It Matters for Investors: ✅ All 14 patients to date have tolerated treatment well ✅ Trial expanding to @Stanford & @NorthwesternU-boosting reach & visibility ✅ Backed by a $12M CIRM award, validating $CLDI's innovation 📄 redchip.com/stocks/cldi/ne… @CIRMnews @TheLancet $CLDI $AMGN $JNJ $CADL #RedChip #RedChat #CalidiBio #BiotechStocks #Oncology #InvestorUpdate #CancerResearch #FinancialNews

@CalidiBio and @cityofhope have jointly announced progress from a Phase 1 clinical trial using Calidi's CLD-101, a neural stem cell-based oncolytic virotherapy aimed at treating recurrent high-grade glioma. Read more here: ir.calidibio.com/news/news-deta…

📢 Missed the @CalidiBio Investor Webinar? Watch the Replay Now! 🚀 On Wednesday, $CLDI shared key updates on its groundbreaking oncolytic virotherapies, financial strength, and upcoming milestones. 🔎 Key Takeaways: ✅ Advancing glioblastoma & solid tumor treatments with stem cell-based delivery platforms ✅ FDA-cleared Phase 1b/2 trial set to begin enrollment in Q1 2025 ✅ Positioned in a $13B+ market with strong financial backing 🔗 Watch here: youtu.be/3oGqAKjSUSE @CIRMnews @NorthwesternU @cityofhope @TheLancet $CLDI #RedChip #CalidiBio #CLDI #InvestorWebinar #CancerResearch #Oncology #BiotechStocks #OncolyticVirotherapy #FinancialNews

@CalidiBio is thrilled to announce the presentation of new data of our systemic virotherapy RTNova Platform at the @AACR Annual Meeting in April 2025. Read more here: calidibio.com/newsroom/post/…

@CalidiBio recognizes @WendyPizarroEsq as a speaker today, October 21, 2024, at the San Diego Precision in Clinical Trials Summit in San Diego, CA. She will be speaking on Diversity, Equity and Inclusion Strategies in Clinical Trials and Patient Recruitment.

Yesterday, we at @CalidiBio hosted an exciting virtual presentation diving deep into the groundbreaking science and innovative technology we’re developing to combat cancer. If you missed it, don’t worry! Watch the Replay Here: youtu.be/Ta24QP8dI64

Join Us for an Exciting Webinar: Calidi’s Groundbreaking Cancer Treatment 📅 Date: September 11th 🕓 Time: 4:15 PM ET 🔗 Register now: redchip.zoom.us/webinar/regist… #calidi #virotherapy $CLDI

@CalidiBio was recently featured in an article by Fred Grier with @SDbusiness, highlighting the launch of our new subsidiary, Nova Cell. Read more here: sdbj.com/life-sciences/… #calidi #novacell #stemcells #biotech #sandiego $CLDI

📣 Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results. Read more: globenewswire.com/news-release/2… #calidi #virotherapy #stemcells #biotech $CLDI

@CalidiBio is proud to announce the launch of our new subsidiary, Nova Cell, and a $3 million aggregate investment from Dr. Ronald Rigor. Read more below: globenewswire.com/news-release/2… #stemcell #calidi #NovaCell $CLDI